ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors

Journal of Clinical Investigation

Volumn 126, Issue 8, 2016, Pages 2855-2866

  Gordts, Philip L S M ^a,b   Nock, Ryan ^a   Son, Ni Huiping ^c   Ramms, Bastian ^a,b,d   Lew, Irene ^a   Gonzales, Jon C ^a   Thacker, Bryan E ^a   Basu, Debapriya ^c   Lee, Richard G ^e   Mullick, Adam E ^e   Graham, Mark J ^e   Goldberg, Ira J ^c   Crooke, Rosanne M ^e   Witztum, Joseph L ^b   Esko, Jeffrey D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BIELEFELD UNIVERSITY   (Germany)

^e ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN C3; CHOLESTEROL; CHOLESTEROL ESTER; CHYLOMICRON; CHYLOMICRON REMNANT; FATTY ACID; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KETONE BODY; LIPOPROTEIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MESSENGER RNA; PROTEOHEPARAN SULFATE; RETINOL; RETINOL ESTER; SYNDECAN 1; TAMOXIFEN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; KETONE; LIPOPROTEIN TRIGLYCERIDE; LRP1 PROTEIN, MOUSE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIET RESTRICTION; GENE DELETION; HEART; HEPATIC CLEARANCE; HYPERTRIGLYCERIDEMIA; LIPID DIET; LIPID TRANSPORT; MOUSE; NONHUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REGULATORY MECHANISM; SKELETAL MUSCLE; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; C57BL MOUSE; CARDIAC MUSCLE; FEMALE; GENOTYPE; LIVER; LIVER CELL; MALE; METABOLISM; RISK FACTOR; TRANSGENIC MOUSE;

ANIMALS; APOLIPOPROTEIN C-III; FEMALE; GENOTYPE; HEPARIN; HEPATOCYTES; KETONES; LIPOPROTEINS; LIVER; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCARDIUM; RECEPTORS, LDL; RISK FACTORS; TRIGLYCERIDES; TUMOR SUPPRESSOR PROTEINS;

EID: 84987836108     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI86610     Document Type: Article

References (47)

1. Chapman MJ, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32(11):1345-1361.
2. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384(9943):626-635.
3. Thomsen M, Varbo A, Tybjaerg-Hansen A, Nordestgaard BG. Low nonfasting triglycerides and reduced all-cause mortality: a Mendelian randomization study. Clin Chem. 2014;60(5):737-746.
4. Yao Z. Human apolipoprotein C-III-a new intrahepatic protein factor promoting assembly and secretion of very low density lipoproteins. Cardiovasc Hematol Disord Drug Targets. 2012;12(2):133-140.
5. Schonfeld G, George PK, Miller J, Reilly P, Witztum J. Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. Metabolism. 1979;28(10):1001-1010.
6. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science 1990;249(4970):790-793.
7. Maeda N, Li H, Lee D, Oliver P, Quarfordt SH, Osada J. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem. 1994;269(38):23610-23616.
8. Norum RA, et al. Familial deficiency of apolipoproteins A-I and C-III and precocious coronary-artery disease. N Engl J Med. 1982;306(25):1513-1519.
9. Pollin TI, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008;322(5908):1702-1705.
10. Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371(1):32-41.
11. Crosby J, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371(1):22-31.
12. Brown WV, Baginsky ML. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun. 1972;46(2):375-382.
13. Ginsberg HN, et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest. 1986;78(5):1287-1295.
14. Sundaram M, et al. Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J Lipid Res. 2010;51(1):150-161.
15. Graham MJ, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res. 2013;112(11):1479-1490.
16. Gaudet D, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371(23):2200-2206.
17. Foley EM, et al. Hepatic remnant lipoprotein clearance by heparan sulfate proteoglycans and low-density lipoprotein receptors depend on dietary conditions in mice. Arterioscler Thromb Vasc Biol. 2013;33(9):2065-2074.
18. Stanford KI, et al. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J Clin Invest. 2009;119(11):3236-3245.
19. Larsson M, Vorrsjo E, Talmud P, Lookene A, Olivecrona G. Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets. J Biol Chem. 2013;288(47):33997-34008.
20. Jong MC, Rensen PC, Dahlmans VE, van der Boom H, van Berkel TJ, Havekes LM. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J Lipid Res. 2001;42(10):1578-1585.
21. Weinstein MM, et al. Abnormal patterns of lipoprotein lipase release into the plasma in GPIHBP1-deficient mice. J Biol Chem. 2008;283(50):34511-34518.
22. Bharadwaj KG, et al. Chylomicron-and VLDLderived lipids enter the heart through different pathways: in vivo evidence for receptor-and nonreceptor-mediated fatty acid uptake. J Biol Chem. 2010;285(49):37976-37986.
23. Rohlmann A, Gotthardt M, Hammer RE, Herz J. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest. 1998;101(3):689-695.
24. Gonzales JC, Gordts PLM, Foley EM, Esko JD. Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans. J Clin Invest. 2013;123(6):2742-2751.
25. Brahm AJ, Hegele RA. Chylomicronaemia-current diagnosis and future therapies. Nat Rev Endocrinol. 2015;11(6):352-362.
26. Shachter NS, et al. Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice. J Clin Invest. 1994;93(4):1683-1690.
27. Shachter NS, et al. Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl. J Clin Invest. 1996;98(3):846-855.
28. Kypreos KE, Li X, van Dijk KW, Havekes LM, Zannis VI. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype. Biochemistry. 2003;42(33):9841-9853.
29. Merkel M, et al. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem. 2005;280(22):21553-21560.
30. Zheng C, Khoo C, Furtado J, Sacks FM. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense lowdensity lipoprotein phenotype. Circulation. 2010;121(15):1722-1734.
31. Strauss JG, et al. Adenovirus-mediated rescue of lipoprotein lipase-deficient mice. Lipolysis of triglyceride-rich lipoproteins is essential for high density lipoprotein maturation in mice. J Biol Chem. 2001;276(39):36083-36090.
32. Windler E, Havel RJ. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res. 1985;26(5):556-565.
33. Aalto-Setala K, et al. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest. 1992;90(5):1889-1900.
34. Kowal RC, Herz J, Weisgraber KH, Mahley RW, Brown MS, Goldstein JL. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem. 1990;265(18):10771-10779.
35. Ebara T, Ramakrishnan R, Steiner G, Shachter NS. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J Clin Invest. 1997;99(11):2672-2681.
36. Weisgraber KH, Mahley RW, Kowal RC, Herz J, Goldstein JL, Brown MS. Apolipoprotein C-I modulates the interaction of apolipoprotein E with β-migrating very low density lipoproteins (β-VLDL) and inhibits binding of β-VLDL to low density lipoprotein receptor-related protein. J Biol Chem. 1990;265(36):22453-22459.
37. Veniant MM, et al. Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice. J Clin Invest. 1998;102(8):1559-1568.
38. Wyler von Ballmoos MC, Haring B, Sacks FM. The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis. J Clin Lipidol. 2015;9(4):498-510.
39. Mendivil CO, Rimm EB, Furtado J, Sacks FM. Apolipoprotein E in VLDL and LDL with apolipoprotein C-III is associated with a lower risk of coronary heart disease. J Am Heart Assoc. 2013;2(3):e000130.
40. Gaudet D, et al. Antisense Inhibition of Apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med. 2015;373(5):438-447.
41. Hegele RA, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014;2(8):655-666.
42. MacArthur JM, et al. Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J Clin Invest. 2007;117(1):153-164.
43. Noh HL, Okajima K, Molkentin JD, Homma S, Goldberg IJ. Acute lipoprotein lipase deletion in adult mice leads to dyslipidemia and cardiac dysfunction. Am J Physiol Endocrinol Metab. 2006;291(4):E755-E760.
44. Hocquette JF, Graulet B, Olivecrona T. Lipoprotein lipase activity and mRNA levels in bovine tissues. Comp Biochem Physiol B Biochem Mol Biol. 1998;121(2):201-212.
45. Garcia-Arcos I, et al. Adipose-specific lipoprotein lipase deficiency more profoundly affects brown than white fat biology. J Biol Chem. 2013;288(20):14046-14058.
46. Kelley JL, Kruski AW. Density gradient ultracentrifugation of serum lipoproteins in a swinging bucket rotor. Methods Enzymol. 1986;128:170-181.
47. Gordts PL, et al. Impaired LDL receptor-related protein 1 translocation correlates with improved dyslipidemia and atherosclerosis in apoE-deficient mice. PLoS One. 2012;7(6):e38330.